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Carlos O Mendivil1, Ludivina Robles-Osorio2, Edward S Horton2, Osama Hamdy2 and Augusto Enrique Caballero2*Abstract
Background: Hispanics have a high rate of diabetes that exposes them to an increased risk of cardiovascular
disease. We hypothesized that many of the pathophysiological mechanisms that cause atherosclerotic disease may
be present in young Hispanics who do not have clinical diabetes but are at increased risk of developing it.
Methods: We studied 36 young Hispanic adults without diabetes (ages 18–40). Seventeen participants were at
increased risk of developing type 2 diabetes given by overweight and a family history of diabetes on one or both
parents (at risk group). Nineteen participants with normal body-mass index and no parental history of diabetes
constituted the control group. We measured and compared plasma markers of endothelial dysfunction, disturbed
coagulation and fibrinolysis, subclinical inflammation and adipose tissue dysfunction in the at risk and control groups.
Results: Participants at risk of diabetes were more insulin-resistant according to different indicators, and had
significantly higher levels of soluble intercellular adhesion molecule-1 (sICAM-1), tissue plasminogen activator (tPA),
inhibitor of plasminogen activator-1 (PAi-1), high sensitivity C-reactive protein and free fatty acids, signaling the
presence of multiple proatherogenic alterations despite the absence of overt diabetes. Levels of the prothrombotic
molecule PAi-1 were most elevated in participants who were not only at risk of diabetes by the study definition, but
also abdominally obese.
Conclusions: Young adult Hispanics at risk of type 2 diabetes but without overt disease already bear considerably high
levels of markers reflecting processes that lead to the development of atherosclerotic cardiovascular disease.
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People of Hispanic or Latino origin are currently the lar-
gest and fastest-growing minority group in the United
States [1]. Among Hispanics in the United States, the
prevalence of type 2 diabetes mellitus has been increasing
at an astonishingly fast rate during the last three decades.
Between the years 1980 and 2006, this prevalence jumped
from 2.6% to 10.4% [2], an increase equally marked in all
Hispanic subgroups [2]. Type 2 diabetes is a strong cardio-
vascular disease (CVD) risk factor [3], and the dramatic
rise in its prevalence that we are witnessing today is likely
to translate into increased cardiovascular morbidity,* Correspondence: enrique.caballero@joslin.harvard.edu
2Joslin Diabetes Center, Clinical Research Center, Harvard Medical School,
Boston, MA 02115, USA
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reproduction in any medium, provided the ormortality and health costs for the Hispanic population in
the future. This would add to the already significant bur-
den of CVD in the Hispanic population. Not only is CVD
the main cause of death among Hispanics [4], but when
the prevalence of coronary artery calcification is estimated
by ethnicity, Hispanics have the second highest prevalence
after whites [5]. Furthermore, Hispanic immigrants in the
US have a particularly high prevalence of overweight or
obesity, another relevant cardiovascular risk factor [6].
Importantly, Hispanics tend to deposit visceral and sub-
cutaneous abdominal fat as young adults rather than later
in life, so many of the metabolic derangements contribut-
ing to cardiovascular risk in this population may be
present decades before CVD is manifest [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a clinical CVD event, endothelial dysfunction, hy-
percoagulability and subclinical inflammation have
proven to be key pathophysiologic factors [8], and a
number of biomarkers that measure these alterations
have been discovered and developed [9]. Biomarkers
that measure endothelial dysfunction or subclinical in-
flammation are also predictive of the risk of developing
type 2 diabetes [10,11], so they may provide very useful
information for opportune preventive interventions
aimed at both type 2 diabetes and CVD.
Alterations in endothelial homeostasis are present in
individuals who bear risk factors for the development of
type 2 diabetes well before the development of clinical
hyperglycemia [12,13], and prior studies have encoun-
tered high levels of markers of endothelial dysfunction,
coagulation/fibrinolysis alterations and subclinical in-
flammation in Caucasian patients with obesity [14], or
with a family history or a personal diagnosis of diabetes
[15]. A widely held belief is that atherosclerotic disease
is a problem of middle-aged and older adults, and des-
pite some data on Hispanic youth [16], very little is be-
ing done to explore the alterations that mediate the high
burden of CVD among Hispanics, and open opportun-
ities for early intervention focusing on relevant factors.
For this reason, our main study aim was to explore
whether plasma markers of endothelial dysfunction (sol-
uble intercellular adhesion molecule-1 [sICAM-1] and
soluble vascular adhesion molecule [sVCAM]), disturbed
coagulation/fibrinolysis (tissue-type plaminogen activa-
tor [tPA] and plasminogen activator inhibitor-1 [PAi-1]),
subclinical inflammation (high sensitivity C-reactive pro-
tein [hsCRP] and interleukin 6 [IL-6]) are increased,
while markers of adipose tissue function (adiponectin)
are reduced; in young Hispanic adults who do not have
clinical type 2 diabetes but are at increased risk of type 2
diabetes because of their body weight and family history.Research design and methods
The protocol was approved by the Committee on Human
Studies of the Joslin Diabetes Center (JDC) and the Scien-
tific Advisory Committee of the Clinical Research Center
at the Beth Israel Deaconess Medical Center. All research
activities were conducted according to the principles
expressed in the declaration of Helsinki. All participants
provided written informed consent.
The study included young Hispanic adults at risk of de-
veloping type 2 diabetes (“at risk” group), and subjects of
the same age group and ethnic background but without
the selected risk factors for type 2 diabetes (“control”
group). All subjects were Hispanic, between 18 and 40 years
old, and had not participated in any exercise program for
the 6 months prior to the start of the study.We considered a subject Hispanic if both parents
reported to be Hispanic when asked the following ques-
tion: “What ethnic group do you consider that you belong
to?”. For the at risk group, subjects had to have a history
of type 2 diabetes in one or both parents, and a body-mass
index (BMI) above 27 Kg/m2. For the control group, sub-
jects had to have no history of type 2 diabetes in any first
degree relative, and a BMI under 25 Kg/m2. At-risk and
control subjects were matched by age in +/− 5-year
brackets, that is, a participant in the “at-risk” group who
was 30 years old was matched to a control subject of the
same sex, with an age between 25 and 35 years. The exclu-
sion criteria included diagnosed diabetes or treatment
with oral antidiabetic drugs, insulin or lipid-lowering
drugs, pregnancy, smoking, existent cardiovascular dis-
ease, uncontrolled arterial hypertension, renal disease,
proteinuria, cancer, infectious diseases, severe GI diseases,
lung diseases, electrolyte abnormalities, anemia, peripheral
vascular disease, use of beta-blockers, any diuretic, cal-
cium channel blockers, ACE inhibitors, angiotensin recep-
tor blockers, niacin, glucocorticoids, any antineoplastic
agent, antibiotics, psychoactive agents or bronchodilators.
Study subjects were recruited from the offspring of pa-
tients with type 2 diabetes at the Joslin Diabetes Center
and the Beth Israel Deaconess Medical Center in Boston,
notices placed on bulletin boards at the medical center and
in diabetes clinics, or by referral from colleagues. Only one
subject from any given family was included in the study.
For the study protocol, patients arrived at the clinical re-
search center of the JDC after a 12 hour fast, had a full
medical history and physical examination, plus measure-
ment of weight, height, and waist and hip circumferences
by nutrition staff to ensure consistency. Blood samples were
taken for the measurement of plasma markers and general
chemistry. An oral glucose tolerance test (OGTT) was
performed in accordance with World Health Organization
recommendations. The glucose load was calculated as
1.75 grams of glucose/Kg, with a maximum amount of
75 g. Samples for plasma glucose and insulin were collected
at baseline and 30, 60, 90, and 120 min after the oral glu-
cose load.
In the fasting blood samples, we measured glucose, insu-
lin, glycated hemoglobin A1c (A1c), lipids, free fatty acids,
urea nitrogen, creatinine, sVCAM, sICAM-1, PAi-1, tPA,
TNF-alpha, IL-6, hsCRP and adiponectin.
Plasma glucose, total serum cholesterol, triglycerides,
blood urea nitrogen, and creatinine were measured
using the Synchron CX analyzer (Beckman Systems,
Oxford, CT), whereas HDL cholesterol was measured
directly (Polymedco, Cortland Manor, NY). LDL chol-
esterol concentration was estimated by the Friedewald
formula [17] or was directly measured (Polymedco)
if triglycerides were > 250 mg/dl, total cholesterol
was >240 mg/dL, or HDL cholesterol was <35 mg/dL. A1c
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liquid chromatography. Insulin (Immulite, two-site chemi-
luminescent immunometric assay; Diagnostic Products,
Los Angeles, CA), free fatty acids (enzymatic colorimetric
method, NEFA C kit; Waco Chemicals, Richmond, VA),
and all vascular markers and adipocytokines were mea-
sured at the core laboratory of the clinical research center
at the Beth Israel Deaconess Medical Center, Boston,
Massachusetts. Accepted commercial kits used were
sICAM-1 and sVCAM (ELISA; R&D Systems, Minneap-
olis, MN), TNF-alpha and IL-6 (ELISA; R&D Systems),
hsCRP (solid-phase, chemiluminescent immunometric
assay; Diagnostic Products), PAi-1 and tPA (ELISA;
Diagnostica Stago, Parsipanny, NJ), and adiponectin
(ELISA; Linco Research, St. Charles, MI). We evaluated
the glucose and insulin area under the curve (AUC) with
the trapezoidal method: ½ Σ (ti+1 - ti) (yi + yi+1) [18].
Common indexes of insulin sensitivity and insulin secre-
tion were used: homeostasis model assessment (HOMA)
of insulin resistance [19] (HOMA-IR: {fasting insulin
[microU/mL] * fasting glucose [mmol/L]}/22.5), HOMA of
beta-cell function (HOMA beta-cell% = [20 * fasting insu-
lin]/[glucose (mmol/L) - 3.5]), insulin sensitivity index (ISI:
22.5/(fasting insulin [microU/mL]*fasting glucose [mmol/
L]), and the 1/fasting insulin index. We used insulin secre-
tion indexes as the corrected insulin response (CIR: 100 *
30 min insulin/[30 min glucose (mg/dL) * {30 min glucose
(mg/dL) - 70 mg/dL}]) and the insulin-to-glucose ratio:
(30 min insulin [microU/mL] - fasting insulin [microU/
mL])/(30 min glucose [mg/dL] - fasting glucose [mg/dL])
(19). Total body and trunk fat were estimated through dual
energy X-ray absortiometry with a Hologic QDR 4500
densitometer machine (Hologic, Bedford, MA).
Statistical analysis
The sample size was calculated to achieve 80% statistical
power at a two-sided significance level of 0.05 for a t test
in order to identify a difference in the plasma markers of
endothelial function (sICAM-1) of at least 6% between
the groups, based on previous data on overweight adults
[14]. An expected difference between the groups of
30 ng/ml for sICAM, with an expected SD of 27 ng/mL,
would require at least 14 subjects in each of the groups.
Statistical analyses were performed using SPSS for Win-
dows, version 17 (SPSS, Chicago, IL). For all comparative
data, an alpha-error rate of 0.05 and a beta-error rate of 0.2
were considered. The Kolmogorov-Smirnov test was used
to assess the normality assumption of continuous distribu-
tion. The results are presented as means +/− SD, median,
25th-75th percentile intervals (interquartile range), and
percentages, as applicable. For normally distributed con-
tinuous variables, two-sided t tests were used for the com-
parison of differences between groups. Non-normally
distributed continuous variables were compared using theWilcoxon signed-rank test. All categorical variables were
analyzed using the chi-square test or Fisher’s exact test
when applicable. Spearman correlations were performed to
evaluate the association of continuous variables. To explore
the influence of central body fat distribution, we classified
study participants by waist circumference above or below
the respective group median, and compared mean levels of
markers using a two-way ANOVA with level of waist cir-
cumference and risk group as fixed factors.
Results
Thirty-eight subjects were screened for the study, and 2
were excluded due to a diagnosis of diabetes on the oral
glucose tolerance test (OGTT), for a final sample size of
36 subjects: 19 in the control group and 17 in the at risk
group. There were 9 women in the control group and 10
women in the at risk group. As discovered in the OGTT, 5
participants in the at risk group had impaired glucose tol-
erance (IGT) (29.4% of the group), and 2 had impaired
fasting glucose (IFG) (11.8% of the group). No participant
in the control group had IFG or IGT.
Participants in the at risk group had by study design a
higher weight and BMI than the control group (Table 1).
They also showed higher mean values of several measures
of body adiposity, but not higher A1c levels. Concerning
plasma lipids, the only significant differences were higher
triglycerides and free fatty acids in the at risk group.
Measures of glucose homeostasis and insulin sensitivity
Fasting plasma glucose levels were significantly higher in
the group at risk (5.25 +/− 0.43 mmol/L) than in the
control group (4.7 +/− 0.32 mmol/L) (p < 0.001). How-
ever, there were no significant differences on plasma glu-
cose levels between groups at subsequent time points of
the OGTT (Figure 1). Insulin levels during the OGTT
were in general higher and more variable in the group at
risk. The difference in fasting plasma insulin was significant
(18.0 +/− 2.3 μUI/mL in the group at risk and 9.8 +/−
5.0 μUI/mL in the control group, p = 0.018), and insulin
levels at time points 60 min and 90 min during the OGTT
were also significantly higher in the group at risk. The
between-groups difference in insulin at 120 min was of bor-
derline statistical significance (p = 0.058).
There was a large and significant (p = 0.02) between-
groups difference in the insulin AUC, with the average
value being almost twice as high in the group at risk as in
the control group (Table 2). Glucose AUC was also signifi-
cantly higher in the group at risk, although the propor-
tional difference between groups was smaller. Participants
in the group at risk also had significantly higher values of
the HOMA-IR index, and a lower Insulin Sensitivity Index
of borderline statistical significance (p = 0.051). Between-
groups differences in other measures of insulin resistance
were not statistically significant.
Table 1 Demographic and clinical characteristics of the
two study groups
Risk group P
Control At risk
N= 19 17 -
Age (years) 28.3 ± 5.6 31.8 ± 5.5 0.07
Female sex (%) 47.3 58.8 0.59
Weight (Kg) 65.4 ± 12.1 87.5 ± 21.0 <0.001
Body mass Index (Kg/m2) 23.0 ± 2.0 32.2 ± 5.9 <0.001
Waist circumference (cm) 78.9 ± 7.5 99.1 ± 14.8 <0.001
Waist-to-hip ratio 0.82 ± 0.06 0.87 ± 0.07 0.014
Whole body fat (%) 24.2 ± 6.4 35.9 ± 7.1 <0.001
Trunk body fat (%) 23.0 ± 5.8 36.7 ± 7.8 <0.001
Systolic blood pressure (mmHg) 105.4 ± 13.7 112.4 ± 9.6 0.09
Diastolic blood pressure (mmHg) 67.9 ± 7.5 74.7 ± 9.7 0.025
Fasting plasma glucose (mmol/L) 4.70 ± 0.32 5.25 ± 0.43 <0.001
OGTT 2 h plasma glucose (mmol/L) 7.03 ± 2.16 8.23 ± 2.74 0.14
Impaired fasting glucose # (%) 0 (0) 2 (11.8) 0.12
Impaired glucose tolerance # (%) 0 (0) 5 (29.4) 0.011
Glycated hemoglobin A1c (%) 5.2 ± 0.2 5.2 ± 0.7 0.6
Total cholesterol (mmol/L) 4.45 ± 0.78 4.34 ± 1.04 0.74
Triglycerides (mmol/L) 0.84 ± 0.45 1.26 ± 0.64 0.026
HDL cholesterol (mmol/L) 1.23 ± 0.40 1.01 ± 0.25 0.067
LDL cholesterol (mmol/L) 2.87 ± 0.71 2.91 ± 1.06 0.91
Triglycerides/HDL cholesterol ratio 1.78 ± 1.2 3.15 ± 1.91 0.015
Plasma free fatty acids (mEq/L) 0.42 ± 0.16 0.58 ± 0.22 0.02
Values are means (SD) unless indicated otherwise.
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inflammation
The group at risk had increased levels of sICAM-1, but
not sVCAM; as well as significantly elevated tPA, PAi-1,
hsCRP and free fatty acids. Adiponectin levels were on
average lower in the group at risk, but this differenceFigure 1 Plasma glucose and insulin concentrations during the OGTT
*P < 0.05, †P < 0.01, ‡P < 0.001.was not significant (p = 0.3). The most pronounced
between-groups difference was evident for the coagula-
tion/fibrinolysis markers (Figure 2). No difference was
observed on circulating TNF-alpha levels.
Relationship between fat distribution and biomarkers
Among participants in the at risk group, those with a waist
circumference above the group median had significantly
higher levels of PAi-1 compared to those with waist cir-
cumferences below the median (Figure 3). Participants in
the at risk group with waist circumferences below the
group median had PAi-1 levels comparable to those of par-
ticipants in the control group. Concentrations of hsCRP
were on average higher among participants with waist cir-
cumferences above their group median, but this difference
did not reach statistical significance in either group.
Correlations between glucose homeostasis indexes
and biomarkers
The highest correlations were observed between PAi-1 or
tPA and the measures of insulin resistance: fasting
insulinemia, insulin AUC and HOMA-IR, Spearman correl-
ation coefficients ranged between 0.67 and 0.71 (p < 0.001
for all correlations). There was also a positive and signifi-
cant correlation of PAi-1 (r = 0.53, 0.001) and tPA (r = 0.65,
p < 0.001) with fasting glucose. sICAM-1 levels were most
strongly correlated with the insulin AUC (r = 0.61,
p < 0.001), but also showed significant correlations with
fasting glucose (r = 0.41, p = 0.011), fasting insulin (r = 0.52,
p < 0.001), HOMA-IR (r = 0.54, p < 0.001) and HOMA-beta
cell (r = 0.37, p = 0.026). Meanwhile, sVCAM did not cor-
relate with any of the performed indexes of glucose metab-
olism. Among the biomarkers of subclinical inflammation,
hsCRP was the one most strongly correlated with metabolic
variables including fasting glucose (r = 0.50, p = 0.002),
fasting insulin (r = 0.50, p = 0.001), insulin AUC (r = 0.48,
p = 0.002), HOMA-IR (r = 0.53, p < 0.001) and HOMA-
beta cell (r = 0.34, p = 0.038). On the other hand, IL-6 wasin the control (light diamonds) and obese (dark squares) groups.
Table 2 Measures of glucose homeostasis and insulin
sensitivity in the two study groups
Risk group P
Control At risk
Insulin AUC
(microUI*min-1*mL-1)
7450 ± 3156.4 11998.1 ± 7343.9 0.020
Glucose AUC
(mg*min-1*dL-1)
14505.8 ± 2718.3 16718.7 ± 3766.8 0.042
Corrected Insulin Response 0.56 ± 1.37 1.09 ± 0.91 0.238
Insulin-to-glucose ratio 1.28 ± 1.45 2.14 ± 1.94 0.129
Insulin Sensitivity Index 0.6 ± 0.27 0.38 ± 0.4 0.051
HOMA-IR 2.11 ± 1.17 4.35 ± 2.79 0.004
HOMA-beta cell 177.4 ± 167.8 203.3 ± 127.6 0.299
1/Insulin 0.13 ± 0.06 0.09 ± 0.08 0.073
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Figure 2 Markers of endothelial activation, coagulation and
fibrinolysis, vascular inflammation, and adipocytokines in the
control (light bars) and at risk (dark bars) groups. The variables
with a normal distribution are shown with bars and SDs, whereas
those not normally distributed are shown in a box plot format.
*P < 0.05, †P < 0.01, ‡P < 0.001.
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circulating TNF-alpha levels only correlated with insulin
AUC (r = 0.34, p = 0.045). Adiponectin was significantly
and negatively correlated with all measures of insulin resist-
ance, coefficients were r = −0.43 (p = 0.01) with fasting glu-
cose, r = −0.46 (p = 0.004) with fasting insulin, r = −0.34
(p = 0.04) with insulin AUC and r = −0.51 (p = 0.001) with
HOMA-IR. Plasma free fatty acids correlated positively
with the glucose AUC (r = 0.48, p = 0.003).
Discussion
In this study in young Hispanic adults without diabetes or
other metabolic disease, an increased risk for type 2 dia-
betes was significantly associated with markers of early
phenomena in the pathogenesis of atherosclerotic disease:
Endothelial activation (higher levels of sICAM-1), subclin-
ical inflammation (higher levels of hsCRP), disturbed co-
agulation/thrombolysis (increased levels of PAi-1 and
tPA), and impaired suppression of adipose tissue lipolysis
(increased levels of plasma free fatty acids). The interpret-
ation of our central finding could be that in young
Hispanic adults without any overt metabolic disease but at
risk of type 2 diabetes, the pathophysiological alterations
that lead to macrovascular disease were already present.
The average age of both the control and the at risk group
was around 30 years, so they do represent young Hispanic
adults, despite the relatively wide range of ages allowed in
the inclusion criteria. This supports the idea that prevent-
ive measures aimed at preventing the silent progression of
cardiovascular disease should be instated since the early
adulthood, particularly among ethnicities disproportion-
ately affected by diabetes and cardiovascular disease, as is
the case among Hispanics.
sICAM-1 is a circulating version of the adhesion mol-
ecule Intercellular Adhesion Molecule-1 (ICAM-1), which
facilitates adhesion of circulating monocytes to endothelial
cells [20]. sICAM is not an entirely endothelium-
specific marker and its levels may increase during acuteinflammatory processes but it has the great advantage
that, being a circulating marker; it allows for a global
evaluation of endothelial function; as opposed to the
local assessment of endothelial function by the meas-
urement of endothelium-dependent vascular reactivity.
In prospective studies, sICAM-1 has been positively as-
sociated with the risk of myocardial infarction among
initially healthy individuals [21,22]. There seem to be
differences in the prognostic meaning of sICAM-1 and
sVCAM: a previous observational study found a positive
association between sICAM-1, but not sVCAM and
Figure 3 Markers of endothelial activation, coagulation, fibrinolysis and vascular inflammation that differed between the control and
at risk groups, by waist circumference below (light bars) or above (dark bars) the median of their risk group. Median waist
circumference was 94 cm in the at risk group, and 80.5 cm in the control group. *p = 0.02 and †p = 0.04 for difference between high and low
waist circumference in a two-way ANOVA that included risk group.
Mendivil et al. Diabetology & Metabolic Syndrome 2013, 5:37 Page 6 of 8
http://www.dmsjournal.com/content/5/1/37atherosclerotic disease, in that case carotid or femoral
plaque burden [23]. The same observation of sICAM-1
being a better predictor was found in a large cohort
study of endothelial markers and symptomatic periph-
eral arterial disease [24]. This evidence suggests that the
elevated sICAM-1 of individuals in the at risk group in
our study signals an increased risk of future CVD des-
pite their apparently healthy condition.
tPA is a serine protease that degrades fibrin, promoting
the dissolution of pre-formed blood clots. PAi-1 is a potent
inhibitor of tPA, what makes it an essentially prothrombotic
mediator, but it also has important profibrotic and chemo-
tactic activities [25]; both tPA and PAi-1 have been reported
to correlate with body weight [26]. The very large between-
groups difference in our study (levels in the at risk group al-
most doubled those in the control group); emphasizes that
apparently healthy young individual at risk for type 2 dia-
betes exhibit remarkable alterations in these markers. An
appealing finding was that PAi-1 levels in the at risk groupwere elevated only among participants with a waist circum-
ference above the group median (a relative measure of ab-
dominal obesity). In other words, the association between
being at risk for type 2 diabetes and PAi-1 levels was mostly
accounted for by abdominal obesity. Prior studies have doc-
umented a strong association between abdominal adiposity
and circulating PAi-1 in subjects without diabetes [27,28].
It has also been shown in animal models that insulin resist-
ance, which is strongly associated with abdominal obesity;
stimulates the production of PAi-1 through the Mitogen-
Activated Kinase pathway [29]. This suggests that interven-
tions focused on reduction of adiposity and improvement
of body fat distribution may have an important positive im-
pact on coagulation disturbances among Hispanics at risk
for type 2 diabetes.
The elevated hsCRP levels of the at risk group confirm
that subclinical inflammation is a key precursor of the
metabolic alterations that foster the appearance of type 2
diabetes. There is a well established association between
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groups difference in hsCRP may be attributed to BMI dif-
ferences; but it was interesting to observe that higher waist
circumferences were associated with higher hsCRP levels
even within the control group. The hsCRP difference be-
tween control subjects above or below the waist circumfer-
ence group median did not achieve statistical significance,
but there was a clear trend towards increased hsCRP in the
relatively more abdominally obese control subjects. The
lack of significance for such a large difference is probably
due to limited sample size and the intrinsically high bio-
logical variability of hsCRP. In any case, the significantly
higher hsCRP levels in the at risk group constitute a
worrying alarm, given that hsCRP correlates strongly with
the long term risk of type 2 diabetes, CVD, stroke and
death [30,31]. The other two inflammatory markers be-
sides hsCRP (IL-6 and TNF-alpha) were not associated
with at risk status, there may be several reasons for this.
IL-6 is known to stimulate production of hsCRP by the
liver, so in a sense hsCRP is an integrated version of IL-6
activity, one that may be more related to chronic systemic
conditions [32]. In the case of TNF-alpha, much of its ac-
tion is exerted at the paracrine level [33], so it is likely that
circulating levels do not reflect actual TNF-alpha secre-
tion, particularly by adipose tissue. Adiponectin levels did
not differ significantly between groups, but there was a
trend towards lower levels in the at risk group. In any
event, in our study reduced adiponectin was not a prom-
inent characteristic of Hispanics at risk for type 2 diabetes.
In our selection of at risk individuals, we combined two
separate risk factors, one modifiable and mostly environ-
mental in nature (overweight) and one non-modifiable
and mostly genetic in nature (family history). For future
studies it will be interesting to explore how much of the
observed alterations in markers can be attributed to each
risk factor separately, as this will have implications in the
development of preventive strategies.
Despite the constellation of other differences in rele-
vant biomarkers between groups, including the presence
of some individuals with IGT and IFG, we did not find
significantly higher A1c values in the at risk group. This
observation brings even more rationale for further stud-
ies that clarify the potential role of A1c as a diagnostic
test to screen for or to diagnose pre-diabetic states, par-
ticularly in this ethnicity and age group [34,35].
Conclusions
Our results suggest that young adult Hispanics at risk of
type 2 diabetes but without clinical or biochemical diabetes
already bear considerably high levels of markers reflecting
processes that promote the development of CVD. In par-
ticular sICAM (endothelial dysfunction), tPA and PAi-1
(hypercoagulability), hsCRP (chronic inflammation) and
plasma free fatty acids (adipose dysfunction) may be earlymarkers of these pathogenic processes. Given the growing
relevance of cardiovascular and metabolic disease in this
population group, these observations constitute a call to
early preventive actions focused on young Hispanics.
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